Carol L. Brosgart, M.D., Chair

Carol Brosgart, M.D., serves as Special Adviser on Health Care for FIPRA International and as a consultant to biotechnology companies. She is a Clinical Professor of Medicine in the Divisions of Global Health Sciences, Biostatistics and Epidemiology in the Department of Medicine at the University of California, San Francisco (UCSF). From 2011 through 2013, she served as the Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the Centers for Disease Control and to the Viral Hepatitis Action Coalition at the CDC Foundation. She has held a number of senior management positions in the medical and biotechnology community including Chief Medical Officer and Senior Vice President at Alios BioPharma, and Senior Vice President and Chief Medical Officer Children’s Hospital & Research Center in Oakland, California. From 1998 to 2009, Dr. Brosgart held a number of senior management positions at Gilead Sciences Inc. including Vice President, Public Health and Policy, Vice President, Medical Affairs, and Vice President, Clinical Research. During her tenure leading clinical research at Gilead, Viread® and Hepsera® were approved by the FDA and regulatory agencies worldwide.

Dr. Brosgart was a practicing physician before joining Gilead, and was the founding Medical Director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, California from 1987 through 1998 and the Medical Director of Central Health Center, Alameda County Health Care Services Agency from 1978-1987. She is active professionally in the Infectious Diseases Society of America, the HIV Medical Association, the American Association for the Study of Liver Disease and the European Association for the Study of Liver Disease. She serves on the Executive Committee of the Forum for Collaborative HIV Research at the University of California Berkeley, School of Public Health and on the Board of Directors of the Pangaea Global AIDS Foundation and the National Viral Hepatitis Round Table. She recently completed six years on the Board of the San Francisco AIDS Foundation. Dr, Brosgart has published extensively in the areas of HIV/AIDS, HBV, HCV and CMV. She received her B.S. in community medicine from the University of California, Berkeley (UCB) and her M.D. from UCSF.

Jordan Feld, M.D., M.P.H

Dr. Feld is an internationally recognized clinical and laboratory researcher in viral hepatitis. He is an Assistant Professor of Medicine at the University of Toronto and a clinician-scientist based at the Toronto Western Hospital Liver Center and the McLaughlin-Rotman Centre for Global Health. His laboratory work focuses on understanding treatment non-response in hepatitis C infection and more broadly on understanding the antiviral immune response with the goal of developing new strategies for the treatment of viral hepatitis. Dr. Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld completed a clinical research fellowship in hepatology and then spent 4 years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health with a focus on Infectious Diseases as a Sommer Scholar from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health.

Philippe Gallay, Ph.D.

Dr. Gallay is Professor, Department of Immunology and Microbial Science at the Scripps Research Institute in La Jolla (San Diego), California. Dr. Gallay holds a Swiss Federal Diploma (MS), from the Institute of Biochemistry, Epalinges, Switzerland and a PhD from Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.  Dr. Gallay’s research program examines the molecular basis of HIV, HCV, and HBV pathogenesis, including characterization of host proteins modulating viral replication, such as various cyclophilins (Host Targeting Antivirals). In particular, Dr. Gallay has studied the role of cyclophilin inhibition on disease progression, and has investigated cyclophilin-NS5A complexes, viral mutations, and synergism with other antiviral compounds, including the Direct Acting Antivirals. Dr. Gallay has presented his research at numerous scientific and research symposia worldwide. He serves as a reviewer for more than 40 journals, has served as a Member on the Center for AIDS Research Developmental Grant Review Committee, and has served as an ad hoc member of the National Institute of Allergy and Infectious Diseases (NIAID), the Medical Research Council (MRC, UK), as well as an ad hoc member of similar committees in Netherlands, Austria, and Switzerland. Dr. Gallay has more than 85 peer-reviewed publications.

Jörg Petersen, M.D, Ph.D.

Dr. Petersen is Full Professor of Medicine and Head of the Liver Unit at the IFI Institute for Interdisciplinary Medicine at the Asklepios Klinik St. George, University of Hamburg, Germany. He received his clinical training at the University of Hamburg, Mount Sinai Medical School, New York, USA, Tulane Medical School, Louisiana, USA and University of Zurich, Switzerland. He is board certified in Internal Medicine, Gastroenterology and Infectious diseases. Dr. Petersen was a research fellow for several years with grant support from the German Research Foundation and the NIH, USA, at the Liver Center of the Albert Einstein College of Medicine, New York.

Dr. Petersen is actively involved in laboratory and clinical research in viral hepatitis and co- leads a work group for the development of novel antiviral techniques in hepatitis B and C. He was a member of the Governing Board of the European Association for the Study of the Liver (EASL) from 2006 to 2009 and he is now acting as an Associated Editor of the Journal of Hepatology, responsible for translational and clinical HBV papers and for clinical HCV papers. He has published more than 100 papers in the field of viral hepatitis and liver diseases and has received a number of honours. He co-authored the recent update of the German guidelines for the diagnosis and treatment of hepatitis B and he was on the review board for the EASL Hepatitis B Clinical Practice Guidelines.

Fabien Zoulim, M.D., Ph.D.

Dr. Zoulim is Professor of Medicine at Lyon I University since 1997. He is currently Medical Director of the Hepatology Department at the Hospices Civils de Lyon, and Scientific Director of the Department of Immunology and Virology of INSERM Unit 1052 where he is leading the team on ‘Antiviral therapy of viral hepatitis’. Dr Zoulim has served as an Associate Editor for Journal of Hepatology and is currently Associate Editor for Gut. He also served as an expert in the microbiology study section of the INSERM and ANRS, and in different national and international committees. He served as a Governing Board member of the European Association for the Study of the Liver (EASL). Dr Zoulim received the William Prusoff award of the International Society for Antiviral Research in recognition of his work in the field of HBV molecular biology and anti-HBV therapy. Furthermore, he has been the scientific coordinator of a European community-funded Network of Excellence on the management of antiviral drug resistance, and is currently involved in several European projects. Fabien Zoulim is a recognised expert in the field of viral hepatitis and antiviral therapy. He has published more than 300 articles (H index 51). Dr. Zoulim obtained his M.D. in Gastroenterology and Hepatology in Lyon Medical School in 1991. He has also obtained a PhD in Molecular and Cellular Biology and was trained as a post-doctoral researcher at Fox Chase Cancer Center in Philadelphia.

Nathaniel Katz, M.D.

Nathaniel P. Katz, M.D., is widely regarded as a global expert in post herpetic neuralgia (PHN) pain management and President and CEO of Analgesic Solutions, a research, education, and consulting firm exclusively focused on pain therapeutics. Dr. Katz is also Adjunct Assistant Professor of Anesthesia at Tufts University School of Medicine. After completing his neurology residency at Tufts-New England Medical Center, he entered a pain management fellowship in the Department of Anesthesia at Brigham & Women’s Hospital in 1990 and was later appointed staff neurologist in the Pain Management Center. Dr. Katz subsequently founded the Pain & Symptom Management Program at Dana-Farber Cancer Institute and the Pain Trials Center at Brigham & Women’s Hospital. Dr. Katz also has previously served as Chair of the Advisory Committee, Anesthesia, Critical Care, and Addiction Products Division at the FDA. Dr. Katz is active in shaping public policy to reduce prescription opioid fraud and abuse, having served as a consultant to the Office of National Drug Policy and other government agencies.

Dr. Katz has completed numerous clinical trials of treatments for pain, both industry-initiated and investigator-initiated, involving pharmaceuticals, non-pharmaceutical analgesics, and devices, and has also conducted studies related to opioids, pain, and addiction. He has over 60 publications in peer-reviewed journals and numerous presentations at scientific congresses. He has served as an Associate Editor at the Clinical Journal of Pain and Associate Editor (Pain) for the Encyclopedia of Neurological Sciences, and has overseen many local and national educational programs on pain management.